An amplified platform nanostructure sensor for the analysis of epirubicin in the presence of topotecan as two important chemotherapy drugs for breast cancer therapy?

New Journal of Chemistry Pub Date: 2018-01-31 DOI: 10.1039/C7NJ04430E

Abstract

Epirubicin (EB) and topotecan (TP) are two major anticancer drugs that are used in breast cancer therapy with many side effects. In this research, we introduce a carbon paste electrode, modified with 1-butylpyridinium hexafluorophosphate and CuO nanoparticles (CPE/1-BPr/CuO-NPs), as an amplified sensor for the electrochemical determination of EB. The electrochemical behavior of EB was initially studied on the surface of CPE/1-BPr/CuO-NPs, CPE/CuO-NPs, CPE/1-BPr, and on bare carbon paste electrodes. The CPE/1-BPr/CuO-NPs showed two separate oxidation signals with a potential of 628 mV and 935 mV in the oxidation of EB and TP, respectively; these potentials are sufficient for determining them simultaneously. The linear response range was found to be 0.03 to 800 μM (R2 = 0.9972) and 0.7 to 800 μM (R2 = 0.9984) for the EB and TP concentrations, with limits of detection (LODs) of 0.008 μM and 0.3 μM, respectively. Finally, the concentrations of EB and TP were successfully measured by CPE/1-BPr/CuO-NPs as a voltammetric sensor in real samples.

Graphical abstract: An amplified platform nanostructure sensor for the analysis of epirubicin in the presence of topotecan as two important chemotherapy drugs for breast cancer therapy
Recommended Literature